Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and on-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-403-6807898
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable
Medicenna Therapeutics (TSE:MDNA) Frequently Asked Questions
What is Medicenna Therapeutics' stock symbol?
Medicenna Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDNA."
When is Medicenna Therapeutics' next earnings date?
What price target have analysts set for MDNA?
1 analysts have issued 1 year price objectives for Medicenna Therapeutics' stock. Their forecasts range from C$4.00 to C$4.00. On average, they expect Medicenna Therapeutics' stock price to reach C$4.00 in the next year. This suggests a possible upside of 128.6% from the stock's current price. View Analyst Price Targets for Medicenna Therapeutics.
What is the consensus analysts' recommendation for Medicenna Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medicenna Therapeutics.
Has Medicenna Therapeutics been receiving favorable news coverage?
Media headlines about MDNA stock have trended very positive on Saturday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medicenna Therapeutics earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Medicenna Therapeutics.
Who are some of Medicenna Therapeutics' key competitors?
Some companies that are related to Medicenna Therapeutics include Resverlogix (RVX), Horizon Discovery Group (HZD), Acasti Pharma (ACST), IMV (IMV), Ergomed (ERGO), Helix Biopharma (HBP), CorMedix (CRMD), Bioventix (BVXP), Fennec Pharmaceuticals (FRX), CorMedix (CRMD), Arix Bioscience (ARIX), IMV (IMV), Ampliphi Biosciences (APHB), Verseon (VSN) and 22nd Century Group (XXII).
What other stocks do shareholders of Medicenna Therapeutics own?
Who are Medicenna Therapeutics' key executives?
Medicenna Therapeutics' management team includes the folowing people:
- Dr. Fahar Merchant, Founder, Chairman, CEO & Pres (Age 62)
- Ms. Rosemina Merchant, Founder, Chief Devel. Officer & Director (Age 62)
- Ms. Elizabeth Williams CPA, CA, CFO & Corp. Sec. (Age 41)
- Dr. Shafique Fidai Ph.D., Head of Discovery & Corp. Devel.
- Dr. John Sampson M.D., Ph.D., MBA, Chief Clinical Advisor
How do I buy shares of Medicenna Therapeutics?
Shares of MDNA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Medicenna Therapeutics' stock price today?
One share of MDNA stock can currently be purchased for approximately C$1.75.
How big of a company is Medicenna Therapeutics?
What is Medicenna Therapeutics' official website?
How can I contact Medicenna Therapeutics?
Medicenna Therapeutics' mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The company can be reached via phone at +1-403-6807898.
MarketBeat Community Rating for Medicenna Therapeutics (TSE MDNA)
MarketBeat's community ratings are surveys of what our community members think about Medicenna Therapeutics and other stocks. Vote "Outperform" if you believe MDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
